Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis. - Wikidata - wikimedia - TriplyDB

Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis.

Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis.

http://www.wikidata.org/entity/Q43687355

about

Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions Long term proton pump inhibitor (PPI) use and incidence of gastric premalignant lesions Probiotics against neoplastic transformation of gastric mucosa: effects on cell proliferation and polyamine metabolism Upper gastrointestinal microbiota and digestive diseases Do we need gastric acid?Analysis of Gastric Body Microbiota by Pyrosequencing: Possible Role of Bacteria Other Than Helicobacter pylori in the Gastric Carcinogenesis.Bacterial flora concurrent with Helicobacter pylori in the stomach of patients with upper gastrointestinal diseases.Survival in hostile territory: the microbiota of the stomach.Reflux disease management strategy: initial therapy.H. pylori and its modulation of gastrointestinal microbiota.Analysis of Gastric Microbiota by Pyrosequencing: Minor Role of Bacteria Other Than Helicobacter pylori in the Gastric Carcinogenesis.Review article: the long-term use of proton-pump inhibitors.Comparison of Gastric Microbiota Between Gastric Juice and Mucosa by Next Generation Sequencing Method Polymorphisms in Toll-like receptor genes and risk of cancer.Helicobacter pylori: host genetics and disease outcomes.Why is the coexistence of gastric cancer and duodenal ulcer rare? Examination of factors related to both gastric cancer and duodenal ulcer.Helicobacter pylori and other gastric bacteria.Premalignant conditions of gastric cancer.Safety of proton pump inhibitors and risk of gastric cancers: review of literature and pathophysiological mechanisms.Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.Proton pump inhibitors and gastric neoplasia.Proton-pump inhibitors: understanding the complications and risks.Helicobacter pylori attenuates lipopolysaccharide-induced nitric oxide production by murine macrophages.Long-term acid suppression by omeprazole in gastro-oesophageal reflux disease patients does not lead to anti-gastric autoantibody production.Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial.

P2860

Q24187480-496A3098-458C-4B6B-9E7C-C20183762479 Q24202377-CC3D4826-3142-45B0-A002-63C86E3757C6 Q26825488-C13401D7-8BFD-4BD8-8170-C7D2F33ED2A4 Q27002380-A2C6C98D-3F96-44AD-9490-377EB336B968 Q33348215-B66A6343-0DC4-4FFD-8F6B-720508FCE5DF Q33888097-2C8295BA-C160-4B15-AB64-753FCD9C4E93 Q34216686-06E36111-8F95-4F83-9A18-B1095E88B34C Q34780560-BDC6434E-B191-4603-8055-BEA8BBFE504E Q35076651-387F01BF-0562-4D70-941B-18C2DF515883 Q35549642-2B2BB33C-C6B5-4A16-B4A7-2FB7A76436A0 Q35936098-D56B64DC-2810-47C5-B437-DB513AA0210F Q36206584-CBAEDF14-BBEB-4EF7-A525-EA43D0758DBF Q36762117-AEF1CA26-4E76-4EE3-88F0-50A1D85C3DFD Q37051040-90E7151C-0E78-48DC-8C19-01FB6C3B6D53 Q37345968-20AEE5DA-7D46-49D5-AE9B-4357489BCD12 Q37830358-DEDA943C-8303-43B2-ADD8-9A6C46B380E9 Q37969590-FB734EB4-9533-4E4B-9617-03BB0688FA34 Q38096470-C4821A91-2570-4C5C-926E-D8C8FC4BA8C8 Q38631128-BD2E6E4A-C0A1-48E1-AFC9-FBCD23F3B0DF Q38865456-38D2686A-71B9-4596-8998-EA7CEB4C99A5 Q41818014-15789B1D-A3A0-4A6E-8C21-25ADC9FB12E9 Q41996131-91F1DCC0-C241-47FC-815E-3197D91B9B6E Q42726769-C610E986-7699-4D6A-8AD3-51DE5B6731C1 Q46424967-BA331586-C3F9-4150-AD7B-0D96E1C209A1 Q46946129-742A1CD5-016E-4BF2-837F-EC4A5143DF50

P2860

Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis.

http://www.wikidata.org/entity/Q43687355

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

Double gastric infection with ...... lopment of atrophic gastritis.

@en

Double gastric infection with ...... lopment of atrophic gastritis.

@nl

type

label

Double gastric infection with ...... lopment of atrophic gastritis.

@en

Double gastric infection with ...... lopment of atrophic gastritis.

@nl

prefLabel

Double gastric infection with ...... lopment of atrophic gastritis.

@en

Double gastric infection with ...... lopment of atrophic gastritis.

@nl

P1433

Q43687355-A98C72E6-DD3F-407B-99EA-222DD595D63A

P1476

Q43687355-06A562E2-985D-40DD-AD56-1ADA95F489C5

P2093

Q43687355-0F5304B3-DD4E-4124-8575-0BE761F43519

Q43687355-8C7E4780-E010-46B8-86C8-1D982A56966D

Q43687355-A13F0843-6ED8-4EE5-8E0A-500B10ABA28D

Q43687355-E35F3520-F863-4B53-B40A-709BA3E65377

Q43687355-FE980B6A-96DA-4676-935B-8A783703831B

P2860

Q43687355-087B1FBA-A667-486E-AE40-47898E3BE36F

Q43687355-23564904-4D97-4C10-9050-03128DAE02EA

Q43687355-2587828F-9ADA-46BA-93F1-A547A6831E61

Q43687355-2AB3C72C-08EB-4021-B489-4EB05506FB06

Q43687355-332E95F6-A33A-42EF-A799-1C88CF0D1E82

Q43687355-383DFAF9-38D8-41D8-B9C5-4A4F8B4D5E72

Q43687355-3C5E73B6-2BA6-40E7-B185-EEF3AE25DE76

Q43687355-458789B6-4AA1-484F-B6D3-040858279650

Q43687355-4B31E59F-4922-41E8-BDDA-FF770A1D22B0

Q43687355-50A9CABD-1E33-4AE3-B3B5-226E6D1E3320

P304

Q43687355-FCADAF4D-C3CB-4F20-A7F3-1D14E958D3F4

P31

Q43687355-16CB9CD4-8EA5-43FC-9E31-ED476FD21EAC

P356

Q43687355-FC72D0B0-9BB1-4F0B-99F6-475CF617D0A4

P407

Q43687355-00CEFEB2-AD2A-4117-AD5B-FA4FDBA8075C

P433

Q43687355-A3B59DF7-8275-4D30-A95D-1E1D7454F300

P478

Q43687355-AC614591-6944-4336-AD4C-E2012CA90D8F

P577

Q43687355-BAF4801C-9C35-4AFF-BCB8-60EEFCF0963F

P5875

Q43687355-D9786484-D010-4C53-8ACF-401E8B0F4FDB

P698

Q43687355-329570F5-A2E8-4358-928E-E3EB946D7F55

P921

Q43687355-A0919505-1D6C-489D-A51D-BFD2CE0CE53E

P356

J.1365-2036.2001.01029.X

P1433

Alimentary Pharmacology & Therapeutics

P1476

Double gastric infection with ...... lopment of atrophic gastritis.

@en

P2093

De Bruïne A

http://www.w3.org/2001/XMLSchema#string

Hameeteman W

http://www.w3.org/2001/XMLSchema#string

Jonkers D

http://www.w3.org/2001/XMLSchema#string

Sanduleanu S

http://www.w3.org/2001/XMLSchema#string

Stockbrügger RW

http://www.w3.org/2001/XMLSchema#string

P2860

Interleukin-1 polymorphisms associated with increased risk of gastric cancer

Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds.

Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole.

Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole.

Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study.

Helicobacter pylori infection and chronic gastric acid hyposecretion.

Intragastric nitrites, nitrosamines, and bacterial overgrowth during cimetidine treatment.

Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication.

Atrophic gastritis and Helicobacter pylori infection in outpatients referred for gastroscopy.

The Sydney System: histological division.

P304

1163-1175

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2036.2001.01029.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2001-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11870927

http://www.w3.org/2001/XMLSchema#string

P698

11472319

http://www.w3.org/2001/XMLSchema#string

P921

Helicobacter pylori